Rick,
Thanks for message. I now see my mistake on p.19 of 10-K, as I was not adding the numbers. It should be interesting to see, given your analysis, how CIST does revenue-wise in next 12-24 months. It looks like a no brainer, when you see where the stock is trading versus the amount of the awards (Immunex + Peprotech), secured patents, and future prospects. Then again, I've been caught with my pants down in the past, and I can only give it my $0.02 as you have done.
By the way, I visited Peprotech's web site (http://www.peprotech.com/) and was very much impressed. I only list it here for anyone here who has not had the chance to view the site. In light of CIST's recent victories over Peprotech and Immunex, it should not be too hard to become a major player, if not the major player, in the expanding cytokine market.
By the way, if I have not mentioned it, I continue to own shares of CIST, and readers should be aware of the risks involved in any investment decision they choose to make. |
